This article was reported by WEHOville.
WEHOville reported that California's Medi-Cal program, which is the state's public insurance program, will no longer require mandatory monthly HIV testing, condom distribution, and pre-authorization as prerequisites for prescribing patients Truvada, an HIV pre-exposure prophylaxis (PrEP). Medi-Cal's requirements sometimes restricted access to its subscribers, who are mainly low-income residents of California. Private insurance companies have covered the drug for some time.
California's leading HIV advocacy groups, AIDS Project Los Angeles (APLA), the L.A. Gay & Lesbian Center, and Project Inform in San Francisco, hailed the announcement. "The Medi-Cal ruling is a game changer in HIV prevention," said Craig E. Thompson, executive director of APLA. "Appropriate access to PrEP through Medi-Cal provides us with another intervention -- along with safer sex and condom use -- to reduce the number of new HIV infections."
Research has shown that Truvada, manufactured by Gilead Sciences, is up to 99 percent effective in preventing disease transmission when an HIV-negative person takes the drug daily and uses condoms. The policy change came after discussions with Medi-Cal and the three aforementioned advocacy groups.
Back to other news for April 2014
This article was provided by CDC National Prevention Information Network.
It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy